History of hypersensitivity reaction to human or mouse antibody products
Human anti-mouse antibody (HAMA) levels of >  ug/ml or human ricin antibodies (HARA) >  ug/ml HARA after cycle 
History of hypersensitivity reaction to human or mouse antibody products
Patients with prior mF, huF, ch. or hu. treatment must have human anti-human antibody (HAHA) antibody titer =<  enzyme-linked immunosorbent assay (Elisa) units/ml; human anti-mouse antibody positivity is allowed
History of hypersensitivity reaction to human or mouse antibody products
LYMPHODEPLETION: Subjects who have received prior therapy with murine antibodies must have documentation of absence of human anti-mouse antibodies (HAMA) prior to lymphodepletion on this study
History of hypersensitivity reaction to human or mouse antibody products
Negative human anti-murine antibody (HAMA) test.
Prior treatment with murine and huF is allowed; patients with prior humanizing murine IgG anti-GD antibody mF (mF), huF, ch. or hu. treatment must have human anti-human antibody (HAHA) antibody titer <  enzyme-linked immunosorbent assay (ELISA) units/ml; human anti-mouse antibody positivity is allowed
Prior treatment with other anti-GD antibodies is allowed (prior treatment with huF is NOT allowed), but human anti-human antibody (HAHA) antibody titer must be =<  enzyme-linked immunosorbent assay (ELISA) units/mL
Absence of human anti?mouse monoclonal antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)
ELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Patients who have received prior therapy with murine antibodies must have documentation of absence of human anti-mouse antibodies (HAMA) prior to enrollment on this study
Human anti-mouse antibody (HAMA) titer >  enzyme-linked immunosorbent assay (Elisa) units/ml
Prior treatment with murine and humanized F is allowed; patients with prior mF, huF, ch. or hu. treatment must have human anti-human antibody (HAHA) antibody titer =<  enzyme-linked immunosorbent assay (Elisa) units/ml; human anti-mouse antibody positivity is allowed
Human anti-huF antibody (HAHA) titer >  Elisa units/ml
Patients previously treated with murine monoclonal antibodies will be excluded if they have a human anti-murine antibody (HAMA) level of >  U/ml
Negative human anti-mouse antibody (HAMA) result.
Absence of human anti-mouse antibodies (HAMA) prior to enrollment for patients who have received prior therapy with murine antibodies
Circulating human anti-mouse antibody (HAMA), to be determined before each infusion
Patients with serum human anti-human antibody (HAHA) against daclizumab
Circulating human anti-mouse antibody (HAMA), to be determined before each infusion
Have a history of hypersensitivity to human or mouse antibody products.
Known allergy to iron dextran or presence of human anti-mouse antibodies
Circulating human anti-mouse antibody (HAMA), to be determined before each infusion
Circulating antibody against mouse immunoglobulin (HAMA)
Human anti-mouse antibody (HAMA) titer <  enzyme-linked immunosorbent assay (Elisa) units/ml if applicable
History of hypersensitivity reaction to human or mouse antibody products
History of hypersensitivity reaction to human or mouse antibody products
Allergy to murine products or positive human anti-mouse antibody (HAMA)
Circulating human anti-mouse antibody (HAMA)
Circulating antibody against mouse immunoglobulin (HAMA)
History of treatment with a murine-derived biological product other than blinatumomab unless subject has been shown to be negative for human-anti-mouse-antibodies (HAMA) prior to or during screening
Has no known allergy to murine products or positive human anti-mouse antibody (HAMA)
History of hypersensitivity reaction to human or mouse antibody products
History of hypersensitivity reaction to human or mouse antibody products
Known positive serology for human immunodeficiency virus (HIV) or human anti-mouse antibody (HAMA)
Prior development of positive human anti-mouse antibody response (HAMA) or human anti-human antibody response (HAHA)
Positive human anti-huF antibody titer
Any patient who has had exposure to mouse or chimeric (human/mouse) immunoglobulin and has antibody to the MA
